XOMA Announces Filing of Registration Statements for Proposed Exchange Offer with the Holders of its 6.50% Convertible Senior Notes due 2012 and $10,000,000 New Money Notes Offering.
In the proposed exchange offer, XOMA would offer up to $60,000,000 aggregate principal amount of its new 6.50% Convertible SNAPs(SM) due 2012 for up to all of the $60,000,000 aggregate principal amount of its currently outstanding 6.50% Convertible Senior Notes due 2012. In addition, the Company also filed a registration statement in connection with its offer to the public of an additional $10,000,000 of the new Convertible SNAPs(SM) for cash.
Piper Jaffray & Co. and Adams Harkness, Inc. are serving as the dealer managers for the exchange offer and placement agents for the cash offer. Wells Fargo Bank, National Association, is serving as the exchange agent in connection with the exchange offer. Registration statements relating to these securities have been filed with the Securities and Exchange Commission but have not yet become effective. These securities may not be exchanged or sold, nor may offers to exchange or offers to buy them be accepted prior to the time the registration statements become effective.
At the time the exchange offer is commenced, XOMA will file a Tender Offer Statement with the Securities and Exchange Commission. The Tender Offer Statement (including the prospectus attached as an exhibit thereto, a related letter of transmittal and other offer documents) will contain important information that should be read carefully before any decision is made with respect to the exchange offer. The prospectus, the related letter of transmittal and certain other offer documents will be made available to all holders of the 6.50% Convertible Senior Notes due 2012 free of charge from the information agent, Georgeson Shareholder Communications Inc., 17 State Street, 10th Floor, New York, New York 10004, (888) 867-6963. The Tender Offer Statement (including the prospectus, the related letter of transmittal and all other offer documents filed with the Securities and Exchange Commission) will also be available for free at the Securities and Exchange Commission's website at http://www.sec.gov.
XOMA is a pioneer and leader in the discovery, development and manufacture of therapeutic antibodies, with a therapeutic focus that includes cancer and immune diseases. XOMA has a royalty interest in RAPTIVA(R) (efalizumab), a monoclonal antibody product marketed to treat moderate-to-severe plaque psoriasis. XOMA's discovery and development capabilities include antibody phage display, bacterial cell expression, and Human Engineering(TM) technologies. The company pipeline also includes proprietary programs in preclinical and clinical development.
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 19, 2005|
|Previous Article:||Universal Express Offers Carmen Electra One Year Luggage Service.|
|Next Article:||Hawk Closes on First Tranche of Financing and Initiates Drilling on the Stanley Line Oil and Natural Gas Project in Lambton County Ontario.|